Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: Implications for local regulation of complement activation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 4, 2003, Pages 630-636

  Oksjoki, Riina ^a   Jarva, Hanna ^b   Kovanen, Petri T ^a   Laine, Petri ^a   Meri, Seppo ^b   Pentikäinen, Markku O ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Atherosclerosis; Complement; Factor H; Proteoglycans

Indexed keywords

COMPLEMENT COMPONENT C3D; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; GLYCOSAMINOGLYCAN; LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN;

AFFINITY CHROMATOGRAPHY; ARTICLE; ATHEROGENESIS; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTIMA; MACROPHAGE; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY MECHANISM; SURFACE PLASMON RESONANCE;

ADULT; AORTA; ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; CHROMATOGRAPHY, AFFINITY; COMPLEMENT ACTIVATION; COMPLEMENT C3D; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; CORONARY VESSELS; HUMANS; MACROMOLECULAR SUBSTANCES; MACROPHAGES; PROTEOGLYCANS; SURFACE PLASMON RESONANCE; TUNICA INTIMA;

EID: 0037387592     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000057808.91263.A4     Document Type: Article

References (49)

1. Bhakdi S. Complement and atherogenesis: the unknown connection. Ann Med. 1998;30:503-507.
2. Torzewski M, Torzewski J, Bowyer DE, Waltenberger J, Fitzsimmons C, Hombach V, Gabbert HE. Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1997;17:2448-2452.
3. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, Gabbert HE, Bhakdi S. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol. 1998;18:369-378.
4. Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, Tranum J, Walev I, Wieland E. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med. 1995;182:1959-1971.
5. Schmiedt W, Kinscherf R, Deigner HP, Kamencic H, Nauen O, Kilo J, Oelert H, Metz J, Bhakdi S. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998;18:1790-1795.
6. Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, Carroll M, Lichtman AH. Influence of C3 deficiency on atherosclerosis. Circulation. 2002;105:3025-3031.
7. Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis. 1989;9:802-811.
8. Kimoto K, Inoue T, Oku K, Mori T, Kusuda M, Handa K, Sakata N, Sasaki J, Arakawa K. Relation of C4b-binding protein to atherosclerosis of the descending thoracic aorta. Artery. 1996;22:101-114.
9. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-1 in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:1233-1238.
10. Niculescu F, Rus HG, Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis. 1987;65:1-11.
11. Seifert PS, Hansson GK. Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J Clin Invest. 1989;84:597-604.
12. Seifert PS, Roth I, Schmiedt W, Oelert H, Okada N, Okada H, Bhakdi S. CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions. Atherosclerosis. 1992;96:135-145.
13. Yasojima K, Schwab C, McGeer EG, McGeer PL. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1214-1219.
14. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol. 1999;163:3957-3962.
15. Öörni K, Pentikäinen MO, Annila A, Kovanen PT. Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans: dependence on oxidative modification of the lysine residues. J Biol Chem. 1997;272:21303-21311.
16. Camejo G, Fager G, Rosengren B, Hurt-Camejo E, Bondjers G. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem. 1993;268:14131-14137.
17. Chao FF, Blanchette-Mackie EJ, Tertov VV, Skarlatos SI, Chen YJ, Kruth HS. Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein to a liposome. J Biol Chem. 1992;267:4992-4998.
18. Jokiranta TS, Zipfel PF, Hakulinen J, Kuhn S, Pangburn MK, Tamerius JD, Meri S. Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett. 1996;393:297-302.
19. Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis. 1989;9:802-811.
20. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386-1392.
21. Zipfel PF, Jokiranta TS, Hellwage J, Koistinen V, Meri S. The factor H protein family. Immunopharmacology. 1999;42:53-60.
22. Friese MA, Hellwage J, Jokiranta TS, Meri S, Peter HH, Eibel H, Zipfel PF. FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated. Mol Immunol. 1999;36:809-818.
23. Meri S, Pangburn MK. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci USA. 1990;87:3982-3986.
24. Pangburn MK, Atkinson MA, Meri S. Localization of the heparin-binding site on complement factor H. J Biol Chem. 1991;266:16847-16853.
25. Blackmore TK, Sadlon TA, Ward HM, Lublin DM, Gordon DL. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J Immunol. 1996;157:5422-5427.
26. Blackmore TK, Hellwage J, Sadlon TA, Higgs N, Zipfel PF. Ward HM. Gordon DL. Identification of the second heparin-binding domain in human complement factor H. J Immunol. 1998;160:3342-3348.
27. Kazatchkine MD, Fearon DT, Silbert JE, Austen KF. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med. 1979;150:1202-1215.
28. Boackle RJ, Caughman GB, Vesely J, Medgyesi G, Fudenberg HH. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway. Mol Immunol. 1983;20:1157-1164.
29. Jansen JH, Høgåsen K, Harboe M, Hovig T. In situ complement activation in porcine membranoproliferative glomerulonephritis type II. Kidney Int. 1998:53:331-349.
30. Levy M, Halbwachs-Mecarelli L, Gubler MC, Kohout G, Bensenouci A, Niaudet P, Hauptmann G, Lesavre P. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int. 1986;30:949-956.
31. Jokiranta TS, Solomon A, Pangbum MK, Zipfel PF, Meri S. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol. 1999;163:4590-4596.
32. Collard CD, Väkevä A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Buras JA, Meri S, Stahl GL. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol. 2000;156:1549-1556.
33. Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med. 1987;111:265-269.
34. Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathol Int. 1995;45:635-641.
35. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis. 1999;145:375-379.
36. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol. 1999;19:2348-2354.
37. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039-1051.
38. Pentikäinen MO, Lindstedt KA, Shiota N, Vehmaan-Kreula P, Laine P, Kovanen PT. C-reactive protein is expressed in human arterial intima. Atherosclerosis. 2000;151:199. Abstract.
39. Hollander W, Colombo MA, Kirkpatrick B, Paddock J. Soluble proteins in the human atherosclerotic plaque: with special reference to immunoglobulins, C3-complement component, alpha 1-antitrypsin and alpha 2-macroglobulin. Atherosclerosis. 1979;34:391-405.
40. Vlaicu R, Rus HG, Niculescu F, Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis. 1985;55:35-50.
41. Cooper NR. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol. 1985;37:151-216.
42. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. ArterioscIer Thromb. 1994;14:32-40.
43. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. 2000;192:1353-1364.
44. Robey FA, Jones KD, Tanaka T, Liu TY. Binding of C-reactive protein to chromatin and nucleosome core particles: a possible physiological role of C-reactive protein. J Biol Chem. 1984;259:7311-7316.
45. Salonen EM, Vartio T, Hedman K, Vaheri A. Binding of fibronectin by the acute phase reactant C-reactive protein. J Biol Chem. 1984;259:1496-1501.
46. Seifert PS, Hugo F, Tranum-Jensen J, Zahringer U, Muhly M, Bhakdi S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med. 1990;172:547-557.
47. Seifert PS, Kazatchkine MD. Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. Mol Immunol. 1987;24:1303-1308.
48. Zarkadis IK, Mastellos D, Lambris JD. Phylogenetic aspects of the complement system. Dev Comp Immunol. 2001;25:745-762.
49. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complementdependent clearance of apoptotic cells by human macrophages. J Exp Med. 1998;188:2313-2320.